Stryker realigns into MedSurg/Neurotechnology and Orthopaedics/Spine segments effective Dec 31, 2021

STRYKER CORP

Segments reflect new internal structure after COO transition; Pierce leads MedSurg/Neuro, Stiles leads Ortho/Spine.
FY 2021 recast sales: MedSurg/Neuro $8,345M, Ortho/Spine $6,006M, total $14,351M.
Q4 2021 recast sales: MedSurg/Neuro $2,429M, Ortho/Spine $1,833M, total $4,262M.
Exhibit 99.1 provides recast historical sales for 2019, 2020, and full-year 2021.
Change aligns with previously announced management responsibilities transition.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.